DESTINY-Breast03 Phase 3 Study Results
Overall Survival Probability (%)
OS in HR+ and All Patients
100
Hormone receptor-positive
Hazard ratio: 0.64
95% CI, 0.48-0.86
P = 0.0028
80
60
40
40
20
20
TPC
MOS: 17.5 mo
T-DXd
MOS: 23.9 mo
A 6.4 mo
Overall Survival Probability (%)
DESTINY-Breast04
100
All patients
Hazard ratio: 0.64
95% CI, 0.49-0.84
P = 0.0010
40
TPC
MOS: 16.8 mo
10
Daiichi-Sankyo
T-DXd
MOS: 23.4 mo
A 6.6 mo
TT
No. at Risk
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Months
No. at Risk
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Months
T-DXD (n = 331): 331 325 323319 314 309 303 293 285 280 268 260 250 228 199 190 168 144 116 95 81 70 51 40 26 14986621
TPC (n=163): 163 151 145 143 139 135 130 124 115 109 104 98 96 89 80 71 56 45 37 29 25 23 16 14 7 5 310
1110
T-DXd (n=373):
TPC (n=184):
373 366 363357 351 344 338 326 315 309 296 287 276 254 223 214 188 158 129 104 90 78 59 48 32 20 14 12 10 8 31110
184 171 165 161 157 153 146 138 128 120 114 108 105 97 88 77 61 50 42 32 28 25 18 16 7 5310
HR, hormone receptor; mOS, median overall survival; OS, overall survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
ASCO 2022 #LBA3 Plenary Session
13View entire presentation